Navigation Links
Diabetes Drug May Boost Weight Loss in Obese Patients
Date:10/23/2009

Combo of diet, exercise and injections helped non-diabetics shed pounds, study finds

FRIDAY, Oct. 23 (HealthDay News) -- The diabetes drug liraglutide helps obese people without diabetes lose weight, researchers have found.

The study authors also reported that high doses of liraglutide were more effective at helping people shed pounds than the weight-loss drug orlistat.

In the study, which included 564 diabetes-free obese patients aged 18 to 65 at 19 sites in Europe, participants were randomly selected to receive one of four injected doses of liraglutide (1.2 milligrams, 1.8 milligrams, 2.4 milligrams or 3 milligrams) or a placebo once a day, or 120 milligrams of orlistat three times a day.

All of the patients also increased their levels of physical activity and followed a calorie-restricted diet, which allowed for about 500 calories less per day than they needed.

Weight loss among patients taking liraglutide doses of 1.2, 1.8, 2.4 and 3 milligrams was 4.8 kilograms (10.5 pounds); 5.5 kilograms (12 pounds); 6.3 kilograms (14 pounds), and 7.2 kilograms (15.8 pounds), respectively, compared with 4.1 kilograms (9 pounds) with orlistat and 2.8 kilograms (6 pounds)with placebo. Weight loss of more than 5 percent occurred in 76 percent of patients taking 3 milligrams of liraglutide, 44 percent of patients taking orlistat, and 30 percent of patients in the placebo group, the researchers found.

Reduced blood pressure was noted in all of the patients taking liraglutide. The groups taking 1.8 to 3 milligrams of liraglutide had an 84 percent to 96 percent reduction in the prevalence of prediabetes, which is poor blood glucose control that's not yet bad enough to qualify as diabetes.

Nausea and vomiting was more common among patients taking liraglutide than among those in the placebo group, the study authors noted.

"The results of this study indicate the potential benefit of liraglutide, in conjunction with an energy-deficit diet, in the treatment of obesity and associated risk factors," wrote Dr. Arne Astrup, of the department of human nutrition at the University of Copenhagen, Denmark, and colleagues.

Additional studies with a follow-up longer than 20 weeks are now needed to investigate the long-term risk/benefit profile of liraglutide, the study authors noted.

The study was released online Oct. 22 in advance of publication in an upcoming print issue of The Lancet.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases outlines the health risks of being overweight.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Adverse housing conditions contribute to diabetes risk
2. RAND finds cases of undiagnosed diabetes drop sharply
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Discovery of sugar sensor in intestine could benefit diabetes
6. Despite overeating, morbidly obese mice gain protection against diabetes
7. Heart Attack Boosts Diabetes Risk
8. Obesity Doesnt Always Equal Diabetes
9. Sugary Sodas High in Diabetes-Linked Compound
10. Treating diabetes during pregnancy can break link to childhood obesity
11. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Los Angeles, CA (PRWEB) , ... February 28, 2017 , ... ... prostate cancer and vasectomies. In studying approximately 800 deaths from prostate cancer, the researchers ... prostate cancer and 20% more likely to get fatal prostate cancer. Although the increased ...
(Date:2/28/2017)... ... February 28, 2017 , ... TruClinic Inc. ... intelligence company based in New York. , “Ensuring an intuitive, user-friendly patient experience ... unaltered. Those two fundamental reasons are the reasons this acquisition is an obvious ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... 2017, from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville ... compliance, performance analytics, and engagement strategies. , The discussion will include best practices ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health ... announces Chris Brandl as its New Guest Director. , Brandl is a ... throughout his career. He began his professional career at Omnium Worldwide, now known ...
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
(Date:2/27/2017)... , Feb. 27, 2017 Mederi Therapeutics ... 28 studies, representing 2468 patients who received  Stretta ... study entitled, " Systematic Review and Meta-Analysis of ... Radiofrequency for Treatment of Gastroesophageal Reflux Disease ", was ... Ronnie Fass , MD, head of the ...
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
Breaking Medicine Technology: